| Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ... The lancet oncology 21 (2), 207-221, 2020 | 712 | 2020 |
| Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial PM Voorhees, JL Kaufman, J Laubach, DW Sborov, B Reeves, ... Blood, The Journal of the American Society of Hematology 136 (8), 936-945, 2020 | 599 | 2020 |
| Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology SK Kumar, NS Callander, K Adekola, L Anderson, M Baljevic, ... Journal of the National Comprehensive Cancer Network 18 (12), 1685-1717, 2020 | 185 | 2020 |
| NCCN guidelines insights: Multiple myeloma, version 1.2020: Featured updates to the NCCN guidelines SK Kumar, NS Callander, J Hillengass, M Liedtke, M Baljevic, ... Journal of the National Comprehensive Cancer Network 17 (10), 1154-1165, 2019 | 148 | 2019 |
| Corneal epithelial findings in patients with multiple myeloma treated with antibody–drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study AV Farooq, S Degli Esposti, R Popat, P Thulasi, S Lonial, AK Nooka, ... Ophthalmology and Therapy 9, 889-911, 2020 | 123 | 2020 |
| Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ... Cancer 127 (22), 4198-4212, 2021 | 114 | 2021 |
| NCCN Guidelines® insights: multiple myeloma, version 3.2022: featured updates to the NCCN guidelines NS Callander, M Baljevic, K Adekola, LD Anderson, E Campagnaro, ... Journal of the National Comprehensive Cancer Network 20 (1), 8-19, 2022 | 105 | 2022 |
| Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium DK Hansen, S Sidana, LC Peres, C Colin Leitzinger, L Shune, ... Journal of Clinical Oncology 41 (11), 2087-2097, 2023 | 96 | 2023 |
| A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma DW Sborov, GJ Nuovo, A Stiff, T Mace, GB Lesinski, DM Benson Jr, ... Clinical cancer research 20 (23), 5946-5955, 2014 | 89 | 2014 |
| Investigational cancer drugs targeting cell metabolism in clinical development DW Sborov, BM Haverkos, PJ Harris Expert opinion on investigational drugs 24 (1), 79-94, 2015 | 83 | 2015 |
| How I manage patients with acquired haemophilia A DW Sborov, GM Rodgers British journal of haematology 161 (2), 157-165, 2013 | 71 | 2013 |
| Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting D Viola, A Dona, E Caserta, E Troadec, F Besi, T McDonald, L Ghoda, ... Leukemia 35 (1), 189-200, 2021 | 65 | 2021 |
| Acquired hemophilia a: a current review of autoantibody disease DW Sborov, GM Rodgers Clin Adv Hematol Oncol 10 (1), 19-27, 2012 | 61 | 2012 |
| Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (pts) with transplant-eligible newly diagnosed … PM Voorhees, JL Kaufman, JP Laubach, DW Sborov, B Reeves, ... Blood 134, 691, 2019 | 50 | 2019 |
| A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T-and B-cell lymphomas DW Sborov, A Canella, EM Hade, X Mo, S Khountham, J Wang, W Ni, ... Leukemia & lymphoma 58 (10), 2310-2318, 2017 | 50 | 2017 |
| HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide A Canella, HC Nieves, DW Sborov, L Cascione, HS Radomska, E Smith, ... Oncotarget 6 (31), 31134, 2015 | 46 | 2015 |
| Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM) S Lonial, AK Nooka, P Thulasi, AZ Badros, BH Jeng, NS Callander, ... Blood cancer journal 11 (5), 103, 2021 | 44 | 2021 |
| Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of … JL Kaufman, JP Laubach, D Sborov, B Reeves, C Rodriguez, A Chari, ... Blood 136, 45-46, 2020 | 43 | 2020 |
| Histone deacetylase inhibitors enhance the therapeutic potential of reovirus in multiple myeloma A Stiff, E Caserta, DW Sborov, GJ Nuovo, X Mo, SY Schlotter, A Canella, ... Molecular cancer therapeutics 15 (5), 830-841, 2016 | 40 | 2016 |
| Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis … JP Laubach, JL Kaufman, DW Sborov, B Reeves, C Rodriguez, A Chari, ... Blood 138, 79, 2021 | 36 | 2021 |
